Zhongguancun Medical Device Park Adds Sixth 'First-of-its-Kind' Product as WanJie TianYuan's Artificial Ligament Earns Beijing Recognition

Recently, the official list of the first batch of major technical equipment recognized as “First Set” in Beijing for 2026 was released.ZhongguancunThe “Artificial Ligament” Developed by Wanjie Medical, a Tenant Enterprise of the Zhongguancun Medical Device Park under Faza Group, Was Successfully Selected. To date, the Zhongguancun Medical Device Park hasCumulative6 ProductsAwarded the First (Set) Certification in Beijing.

Addressing the significant clinical gap in sports medicine, the “Artificial Ligament” independently developed by Wanjie Medical is precisely woven from high-tenacity polyester materials to perfectly replicate human anatomical structures. It serves not only as a functional “substitute” for damaged ligaments but also as a “scaffold” for autologous tissue regeneration, embodying the innovative concept of “composite ligaments,”Addresses the industry pain points of slow recovery and high failure rates associated with traditional repair methods。

The five previously selected first-of-their-kind innovative products from the industrial park have established technological leadership in their respective fields.Neurosurgery Field: withSinovationrepresented by its portable neurosurgical proceduresRobot(Q300 series), 3D structured light surgical robot (SR1-3D), and MRI-guided laser ablation device (LS-1)—four products in total—establishing a comprehensive system of precision diagnostic and therapeutic equipment for neurosurgery.Cardiovascular Field：Percutek TherapeuticsR&D"Integrated Stent System for Intraoperative Artificial Grafts"A world-first innovation that successfully addresses the surgical challenges of Stanford Type A aortic dissection, filling a domestic gap.

From the multiple surgical robots that established industry benchmarks in neurosurgery by Sinovation, to Percutek Therapeutics’ “integrated stent-graft for intraoperative use” that conquered Stanford Type A aortic dissection in the cardiovascular field, and further to recent breakthroughs in biomaterials, the innovation achievements of the industrial park in the high-end medical device sector are advancing from isolated breakthroughs toward clustered development.Covering key sectors such as neurosurgery, cardiovascular medicine, and biomaterials。

The emergence of each “first-of-its-kind” product represents the fruit of a company’s deep technological cultivation and stands as a testament to the innovation nurtured within this fertile park ecosystem. From the nascent stages of technology in the laboratory to clinical applications under surgical lights, Zhongguancun Development Group has consistently served as a “partner” in scientific and technological innovation, running side by side with enterprises over the long haul. By establishing a full-stack integrated service system covering the entire corporate lifecycle, the Group precisely channels innovative resources—such as policy support, capital, and clinical access—to where they are most needed by enterprises.

Zhongguancun Development Group will continue toCultivating the Fertile Ground of the Life and Health Industry,Cultivate a robust innovation ecosystem to enable more original “0-to-1” breakthroughs to move from the laboratory to the production line, injecting a continuous stream of “Zhongguancun strength” into the self-reliance and controllability of China’s medical equipment industry and the advancement of the Healthy China initiative.

Source | Here is Daxing Zhongguancun Medical Device Park